Affronꢁ L y cols. Calidad de vida luego de simpaꢁcotomía toracoscópica por hiperhidrosis. Rev Argent Cir 2021;113(4):419-426
425
Discussion
of quality of life in most paꢀents who underwent
VATS, independently of the levels of resecꢀon used as
1
8
Henry Pancoast was the first to describe observed in other recent studies .
the effects of destrucꢀve lesions of the first thoracic
In our series, 25% of the paꢀents presented
ganglion and the stellate ganglion and included dysesthesia and pain in the thoracic wall associated
anhidrosis and pallor ipsilateral to the tumor among with injury of the intercostal nerve. These complicaꢀons
1
2,13
.
the signs of his syndrome
are usually transient and are not related to the level of
Thereaꢂer, facial hyperhidrosis was managed postoperaꢀve saꢀsfacꢀon. Maya et al.19 reported a rate
by secꢀoning the sympatheꢀc chain at this level. The of complicaꢀons of 0.2% including chylothorax and lung
pioneers of surgical treatment of palmar hyperhidrosis or vascular injury; yet, none of our paꢀents developed
realized that, paradoxically, sympatheꢀc denervaꢀon these complicaꢀons and there were no deaths.
20
For Mena et al. , compensatory hyperhidrosis
produced in the face an effect opposite to that of the
palmar region (pallor due to vasoconstricꢀon instead was the most common secondary effect of VATS with
of flushing and warmth due to vasodilataꢀon), thus an incidence between 35 and 80%. However, for Liꢄle
1
3
8
et al. the relaꢀonship between the frequency and
improving flushing .
There are many publicaꢀons supporꢀng severity of compensatory hyperhidrosis and the extent
thoracoscopic sympathectomy for the management of sympatheꢀc chain resecꢀon is not clear, as different
1
4
of palmar and axillary hyperhidrosis ; moreover, the results have been reported in the literature.
number of sympathectomies performed through video- In our study, 61% of the cases developed mild
assisted thoracoscopy has significantly increased in compensatory hyperhidrosis, but we did not observe
1
0
most departments of thoracic surgery .
associaꢀons with the thoracic level intervened, and in
On the other hand, the use of quality-of- only 1 case (2.5%) the paꢀent reported a reducꢀon in
life quesꢀonnaires has become an important tool for postoperaꢀve quality of life.
quanꢀfying medical outcomes, since psychosocial
Although we understand that the limitaꢀons of
factorshavemajorimplicaꢀonsforabeꢄermanagement our study are the retrospecꢀve nature and the sample
1
5
of the disease .
size, quality of life improved with this procedure in
Thoracoscopic sympathicotomy has proved to 97% of the sample analyzed. We also understand that
be effecꢀve in increasing the quality of life of paꢀents this change could have been beꢄer reflected with a
1
4
with hyperhidrosis, and this effect is stable over ꢀme . preoperaꢀve survey.
Non-surgical treatments for hyperhidrosis
In the future, randomized, double-blind studies
are relaꢀvely effecꢀve but transient. Treatment could confirm if this trend could become the standard
with botulinum toxin is painful and expensive. In a of care for this condiꢀon with such a high social impact.
randomized and controlled study, Bushara et al.16
evaluated 43 paꢀents with consecuꢀve injecꢀons of
1
00 U of toxin versus 200 U, and obtained favorable Conclusion
results aꢂer 96 weeks of follow-up, reducing axillary
sweaꢀng. This treatment is not applicable for palmar
Bilateral thoracoscopic sympathectomy is sꢀll
or facial hyperhidrosis due to the intense pain it the most efficient treatment for hyperhidrosis of palms,
causes. axillae and face. The technique is applicable and safe,
The Society of Thoracic Surgeons, Alabama , and improves paꢀents’ quality of life with a high level
recommends surgery for all paꢀents with palmar and/ of saꢀsfacꢀon.
or symptomaꢀc hyperhidrosis with severe symptoms
96%).
1
7
Compensatory sweaꢀng of sꢀll the most
common complicaꢀon and is mild and transient in most
Yuncu et al. reported excellent results in terms cases.
(
Referencias bibliográficas /References
1
.
Keller S. Simpaꢀcotomia toracoscópica por hiperhidrosis
y
T4. Interact Cardiovasc Thorac Surg. 2011;12(4):545-8.
5. Abtahi-Naeini B, Naeini FF, Adibi N, Pourazizi M. Quality of life
in paꢀents with primary axillary hyperhidrosis before and aꢂer
treatment with fracꢀonated microneedle radiofrequency. J Res
Med Sci. 2015;20(7):631-5.
trastornos vasomotores. En: Sugarbaker DJ. Cirugía del tórax.
Buenos Aires: Editorial Médica Panamericana; 20|5 Cap 121, pp.
1
008-15.
2
3
. Wiꢄmoser R. Treatment of sweaꢀng and blushing by endoscopic
surgery. Acta Neurochir (Wien). 1985;74(3-4):153-4. PMID:
6. Heckmann M, Plewig G. Low-dose efficacy of botulinum toxin A
for axillary hyperhidrosis: a randomized, side-by-side, open-label
study.Arch Dermatol. 2005;141(10):1255-9.
3
984794.
. Berthin C, Millard H. Duraꢀon of efficacy increases with the
repeꢀꢀon of Botulinum Toxin A injecꢀons in primary axillary
a 15-year study in 117 paꢀents. Acta Derm
Venereol. 2019;99(13):1237-40.
. Ishy A, de Campos JR, Wolosker N, Kauffman P, Tedde ML,
Chiavoni CR, et al. Objecꢀve evaluaꢀon of paꢀents with palmar
hyperhidrosis submiꢄed to two levels of sympathectomy: T3 and
7. Miller JL. Diseases of the eccrine and apocrine sweat glands. In:
Bolognia JL, Schaffer JV, Cerroni L (eds). Dermatology. 4th ed.
Philadelphia, PA: Elsevier; 2018. Chap 39.
8. Hornberger J, Grimes K, Naumann M, et al.; Mulꢀ-Specialty
Working Group on the Recogniꢀon, Diagnosis, and Treatment
of Primary Focal Hyperhidrosis. Recogniꢀon, diagnosis, and
hiperhidrosis:
4